ArticleCancer immunology, immunotherapy : CII2026
Survival outcomes of conversion curative therapy following atezolizumab-bevacizumab in advanced hepatocellular carcinoma.
Ying-Hsin Chen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.